Jonathan Silverstein

Avanir Pharmaceuticals, Inc. engages in the development of therapeutic products for the treatment of nervous system disorder. The company was founded on August 31, 1988 and headquartered in Aliso Viejo, CA.

Bioenvision, Inc. engages in the acquisition, development, distribution, and marketing of compounds and technologies for the treatment of cancer. It also develops anti-infective technologies, which includes the OLIGON(R) technology. The company was founded by Christopher B. Wood on August 16, 1996 and is headquartered in New York, NY.

Adolor Corp. is a biopharmaceutical company specializing in the discovery, development and commercialization of novel prescription pain management products. The company develops and commercializes of novel opioid receptor-targeted therapeutics designed to maintain or improve pain relief and reduce opioid-related side effects. Its commercial product ENTEREG is a small molecule, peripherally acting mu opioid receptor antagonist intended to block the adverse side effects of opioid analgesics like morphine, on the gastrointestinal tract without interfering with central nervous system and mediated analgesia. The company was founded in 1993 and is headquartered in Exton, PA.

Given Imaging Ltd. develops, manufactures, and markets diagnostic products and related medical monitoring equipment. Its solutions include capsule endoscopy, manometry, reflux monitoring and monometry. The company was founded by Gabi Iddan and Gavriel D. Meron in 1998 and is headquartered in Yokneam, Israel.

DOV Pharmaceutical, Inc. discovers and develops novel drugs. It focuses on the development of novel product candidates for disorders of the central nervous system, or CNS. It have drug development programs that are at the preclinical, Phase I and Phase II clinical stages, including DOV 21,947 (in a Phase II clinical trial for depression), DOV 102,677 (which has completed a Phase I clinical trial) and a preclinical discovery program in reuptake inhibitors and GABA modulators. The company was founded by Arnold S. Lippa in May, 1995 and is headquartered in Somerset, NJ.

Peninsula Pharmaceuticals, Inc. used to develop and commercialize antibiotics to treat life threatening infections. The company used to develop optimal anti-infective therapies that offer improved efficacy, dosing and safety characteristics over existing therapies. It was founded in 2001. The company was located in Alameda, CA.

Predix Pharmaceuticals, Inc. develops novel drugs and other related products. It is a clinical stage drug development company that uses proprietary discovery and lead optimization engine to develop novel drugs for G-protein coupled receptor (GPCR) and ion channel targets. The company was founded by Silvia Noiman, Haim Aviv, Oren M. Becker and Oren M. Ramot in September, 2002 and is headquartered in Woburn, MA.

Adiana, Inc. develops contraceptive medical devices. It engages in the development and testing of transcervical sterilization system for permanent birth control. The company was founded by Peter Breining in July 1997 and is headquartered in Redwood City, CA.

DFINE, Inc.engages in the development and commercialization of medical device system for treating vertebral compression fractures. The company was founded by John H. Shadduck and Csaba Truckai in 2004 and is headquartered in South Jordan, UT.

Cerexa, Inc. develops biopharmaceutical products. It is focuses on developing, acquiring and commercializing antibiotics to treat life-threatening, hospital-based infections. Cerexa's compound PPI-0903 is a cephalosporin used in treatment for complicated skin and skin-structure infections, as well as community-acquired and hospital-acquired pneumonias. The company was founded in 2005 and is headquartered in Alameda, CA.

Avedro, Inc. develops ophthalmic medical devices and pharmaceutical products. The firm’s products include KXL System, Mosaic system, IROC system and Riboflavin family. Its procedure includes Lasic Xtra, accelerated cross-linking and photorefractive intrastromal cross-linking. The company was founded by David F. Muller and B. Stuart Trembly on November 6, 2002 and is headquartered in Waltham, MA.

Gelesis, Inc. operates as a consumer-centered biotherapeutics company, which engages in the development of novel therapies to induce weight loss and metabolic disorders. Its commercial product portfolio includes Plenity, an FDA-cleared product to aid in weight management, as well as potential therapies in development for patients with Type 2 Diabetes, Non-alcoholic Fatty Liver Disease /Non-alcoholic Steatohepatitis, and Functional Constipation. The company was founded by Yishai Zohar in 2006 and is headquartered in Boston, MA.

Cerapedics, Inc. engaged in the provision of developing and commercializing novel osteobiologic products. It offers i-FACTOR Bone Graft, an advanced biologic that supported with level I evidence, and provides benefit ratio. The company was founded by Andrew J. Tofe and is headquartered in Westminster, CO.

Sorrento Tech, Inc., also known as Roka Bio Science, is a private company that specializes in food safety technology. The company is based in Warren, NJ and has subsidiaries in the United States. The company's core technology is the Roka pathogen detection assays, which combine the power of target capture, transcription-mediated amplification, and hybridization protection assay to deliver a fully automated, single-protocol assay with reduced enrichment times and superior sensitivity. The company's products include the Atlas® system and various detection assays for E. coli, Listeria, Salmonella, Campylobacter, and Legionella. Roka Bio Science provides solutions for the beef, dairy, pet food, poultry, produce, ready-to-eat foods, spices and ingredients, and environmental testing industries. Roka Bio Science was founded in 2009 by Paul G. Thomas.

Auxillium Energy, Inc. is an exploration stage company. It engages in the investigation, acquisition, exploration and development of oil and gas properties in Alaska. The company was founded on November 9, 2009 and is headquartered in White Plains, NY.

Arteaus Therapeutics LLC develops therapies for migraine prevention. The company was founded by Dave Grayzel and Scott C. Chappel on July 15, 2011 and is headquartered in Cambridge, MA.

The Sumitomo Bank of California is a state commercial bank. The company is based in San Francisco, CA.

NxStage Medical, Inc. is a medical technology company, which develops, manufactures, and markets products for the treatment of ESRD and acute kidney failure. It operates through the following business segments: System One, In-Center, and Services. The System One segment engages in the sale and rental of the System One and PureFlow SL equipment and the sale of disposable products in the home and critical care markets. The In-Center segment sells blood tubing sets and needles for hemodialysis primarily for the treatment of ESRD patients at dialysis centers and needles for apheresis. The Services segment includes revenues from dialysis services provided to patients at its recently opened NxStage Kidney Care dialysis centers. The company was founded by Jeffrey H. Burbank in December 1998 and is headquartered in Waltham, MA.

Emphasys Medical, Inc., a medical technology company, focuses on developing and commercializing minimally invasive therapeutic devices for the treatment of patients with emphysema and other breathing disorders. It offers Zephyr Endobronchial Valve system, which is designed to block air from passing through the opening in the lung and into the chest cavity, resulting in the reduction or elimination of airflow through the leak to allow the tissue to heal. The company offers its products through distributors and dealers in Europe, Australia, Hong Kong, and Singapore. Emphasys Medical was founded in 2000 and is based in Redwood City, CA. Emphasys Medical, Inc. operates as a subsidiary of Pulmonx Corp.

superDimension Ltd. develops and markets pulmonology devices. Its devices enable the diagnosis and potentially the treatment of distal lung disease. The firm develops and markets catheter-based devices for use in the invasive diagnosis and treatment of early stage lung cancer and other diseases, using the patient's natural airways to avoid surgery. The company was founded by Pinchas Gilboa in 1995 and is headquartered in Herzliya, Israel.

Enobia Pharma, Inc. develops therapies to treat patients with ultra-rare and life-threatening genetic metabolic bone disorders. Its lead product candidate, asfotase alfa or ENB-0040, is a treatment for hypophosphatasia—a life-threatening disease that can cause skeletal deformity, severe muscle weakness and progressive damage to vital organs. The company was founded in 1997 and is headquartered in Montreal, Canada.

OrbiMed Advisors Private Equity (OrbiMed Advisors Private Equity) is a private equity and venture capital subsidiary of Orbimed Advisors LLC founded in 1993 by Samuel D. Isaly. The firm is headquartered in New York and it has additional offices in San Francisco, Mumbai, Shanghai, Herzliya, Hong Kong and London.

Relypsa, Inc. operates as a bio-pharmaceutical company, which engages in the development and commercialization of late-stage medicines in the iron deficiency, nephrology, and cardio-renal therapeutic areas. It offers Veltassa, a potassium binder approved for the treatment of hyperkalemia. The company was founded by Jerry M. Buysse, Gerrit Klaerner, Michael Burdick, Jay P. Shepard, Detlef F. Albrecht, George Tyson, Sandra I. Coufal and Vic Ciaravino on October 29, 2007 and is headquartered in Redwood City, CA.

SuperDimension, Inc. used to develop and market pulmonology devices. It developed and used to market catheter-based devices for use in the invasive diagnosis and treatment of early stage lung cancer and other diseases, using the patient's natural airways to avoid surgery. The company was founded by Pinhas Gilboa in 1995 and was headquartered in Minneapolis, MN.

Allergan GI Corp. develops peptide therapeutics for the treatment of gastrointestinal disorders. It provides RM-493 a small-peptide melanocortin-4 receptor agonist, for the treatment of obesity and diabetes, and RM-131 a small-peptide ghrelin agonist, for the treatment of diabetic gastro paresis and other gastrointestinal functional disorders. The company was founded by Bart Henderson and Elizabeth Stoner in 2008 and is headquartered in Madison, NJ.

Astellas Gene Therapies, Inc. is a biotechnology company, which engages in the development and commercialization of gene therapy products for patients with serious and rare diseases caused by single gene defects. The company was founded by Matthew R. Patterson and Thomas J. Schuetz on November 13, 2012 and is headquartered in San Francisco, CA.

Adicet Therapeutics, Inc. operates as a biopharmaceutical company focuses on the development of cell immunotherapies. It engages in the design and development of immunotherapies for cancer and other disease indications with a focus on novel universal immune cell therapies. The company was founded by Aya Jakobovits in 2014 and is headquartered in Beverly Hills, CA.

resTORbio, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the development and commercialization of medicines for aging-related diseases and conditions. It offers an immunotherapy under the TORC1 program. The company was founded by Chen Schor and Joan Mannick on July 5, 2016 and is headquartered in Boston, MA.

Greatest Common Factory LLC provides marketing and advertising services. The company was founded by John Trahar in 2011 and is headquartered in Austin, TX.